Stacey Ishley
Psychiatric/Mental Health · Wilkes Barre, PANPI 1255712956
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 26.2% of the total. 2025 is the largest year on record at $1,909, more than ten times the $131 reported in 2021. Among psychiatric/mental health clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Johnson & Johnson$691
- Otsuka America Pharmaceutical, Inc.$550
- Alkermes, Inc.$402
- AbbVie$392
- Supernus Pharmaceuticals, Inc.$359
- plus $774 from 7 others
What the payments were for
- Food & beverage$4,293100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 34 | $1,125 |
| Johnson & Johnson | 25 | $691 |
| Otsuka America Pharmaceutical, Inc. | 30 | $550 |
| Alkermes, Inc. | 19 | $402 |
| AbbVie | 25 | $392 |
| Supernus Pharmaceuticals, Inc. | 20 | $359 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $276 |
| E.r. Squibb & Sons, L.L.C. | 11 | $160 |
| Corium, LLC | 9 | $122 |
| Neurocrine Biosciences, Inc. | 6 | $87 |
| Axsome Therapeutics, Inc. | 3 | $61 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$369
- UZEDY$230
- INVEGA SUSTENNA$156
How this compares
$4,293 in reported general payments places this provider in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Risperidone | 14 | $116 |
| Citalopram HbrCitalopram Hydrobromide | 18 | $62 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Wilkes Barre
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Michelle CohenWashington$62K
- Sharon KatzJenkintown$51K
- Jennifer BowmanCanonsburg$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.